China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2026)

China SXT Pharmaceuticals has reported Other Accumulated Expenses for 9 years, with the latest figure at $74922.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 28.85% year-over-year to $74922.0 in Q1 2026; TTM through Mar 2026 was $74922.0, a 28.85% increase from a year earlier, with the FY2026 full-year figure at $74922.0, up 28.85% from the prior year.
• Other Accumulated Expenses was $74922.0 for Q1 2026 at China SXT Pharmaceuticals, down from $920853.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.2 million in Q1 2022, with the low at $58145.0 in Q1 2025.
• Average Other Accumulated Expenses over 5 years is $648297.0, with a median of $789232.0 recorded in 2023.
• The largest YoY upside for Other Accumulated Expenses was 98.08% in 2025 against a maximum downside of 83.92% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $1.0 million in 2022, then declined by 5.56% to $972738.0 in 2023, then plunged by 52.21% to $464886.0 in 2024, then surged by 98.08% to $920853.0 in 2025, then slumped by 91.86% to $74922.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $74922.0 (Q1 2026), $920853.0 (Q3 2025), and $58145.0 (Q1 2025), per Business Quant data.